BTS 74,398

From Wikipedia, the free encyclopedia
BTS 74,398
Systematic (IUPAC) name
1-([1-(3,4-dichlorophenyl)cyclobutyl]-2-(3-diaminethylaminopropylthio)ethanone
Clinical data
Legal status ?
Identifiers
ATC code ?
PubChem CID 24838024
ChemSpider 26325181 YesY
Chemical data
Formula C19H29Cl2N3OS 
Mol. mass 418.423 g/mol
 YesY (what is this?)  (verify)

BTS 74,398 is a centrally acting stimulant drug which was developed for the treatment of Parkinson's disease. It inhibits the synaptic reuptake of dopamine, serotonin and noradrenaline, making it a triple reuptake inhibitor.[1] It was effective in animal models of Parkinson's disease,[2][3] but was unsuccessful in human trials.[4]

References

  1. ↑ Lane EL, Cheetham S, Jenner P. Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. Journal of Pharmacology and Experimental Therapeutics. 2005 Mar;312(3):1124-31. PMID 15542624
  2. ↑ Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates. Movement Disorders. 2004 Jan;19(1):15-21. PMID 14743355
  3. ↑ Lane EL, Cheetham SC, Jenner P. Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours. European Journal of Neuroscience. 2005 Jan;21(1):179-86. PMID 15654855
  4. ↑ Lane EL, Cheetham S, Jenner P. Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398. Journal of Neural Transmission. 2008;115(3):423-9. PMID 18250952


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.